Published in Antimicrob Agents Chemother on July 01, 2003
Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther (2009) 1.03
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother (2010) 0.98
Antiretroviral bioanalysis methods of tissues and body biofluids. Bioanalysis (2013) 0.94
How much do antiretroviral drugs penetrate into the central nervous system? J Med Life (2011) 0.91
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother (2012) 0.90
ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis (2014) 0.82
Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study. PLoS One (2013) 0.78
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet (1986) 4.54
Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest (1998) 3.66
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol (1997) 2.92
Primary human T-lymphotropic virus type III infection. Ann Intern Med (1985) 2.40
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis (2000) 2.10
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem (1994) 2.07
Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clin Pharmacol Ther (2000) 1.92
Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology (1994) 1.88
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos (2000) 1.87
Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother (1998) 1.60
Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy. Clin Infect Dis (1999) 1.58
HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol (1999) 1.51
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS (2000) 1.26
Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers. Antimicrob Agents Chemother (2001) 1.24
Pharmacokinetic evaluation of stable piecewise cubic polynomials as numerical integration functions. J Pharmacokinet Biopharm (1989) 1.19
Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS (1998) 1.18
Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos (1996) 1.08
Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol (2000) 1.04
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res Hum Retroviruses (2000) 1.02
Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy. AIDS (1998) 0.87
Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy. Lancet (1997) 0.78
Foscarnet activity on human immunodeficiency virus type 1 in the central nervous system. Clin Infect Dis (1999) 0.78
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med (2010) 8.72
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med (2006) 3.25
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Active adaptation of the tethered mitral valve: insights into a compensatory mechanism for functional mitral regurgitation. Circulation (2009) 2.08
CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis (2005) 1.81
Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations. Arthritis Rheum (2005) 1.79
Nomenclature and definitions for emergency department human immunodeficiency virus (HIV) testing: report from the 2007 conference of the National Emergency Department HIV Testing Consortium. Acad Emerg Med (2008) 1.62
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother (2006) 1.55
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr (2004) 1.48
Polyethylene glycol versus sodium phosphate mechanical bowel preparation in elective colorectal surgery. Am J Surg (2007) 1.43
A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials (2003) 1.42
Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry (2003) 1.27
Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis (2003) 1.20
Anger and pain sensitivity in chronic low back pain patients and pain-free controls: the role of endogenous opioids. Pain (2002) 1.19
Implementation and evaluation of a clinic-based behavioral intervention: positive steps for patients with HIV. AIDS Patient Care STDS (2008) 1.18
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis (2006) 1.18
Psychosocial characteristics and sexual behaviors of people in care for HIV infection: an examination of men who have sex with men, heterosexual men and women. AIDS Behav (2009) 1.12
Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer (2011) 1.12
A kinematic analysis of a judo leg sweep: major outer leg reap--osoto-gari. Sports Biomech (2003) 1.12
Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother (2011) 1.12
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol (2005) 1.10
Genetically programmed in vivo packaging of protein cargo and its controlled release from bacteriophage P22. Angew Chem Int Ed Engl (2011) 1.08
White Paper Report of the 2010 RAD-AID Conference on International Radiology for Developing Countries: identifying sustainable strategies for imaging services in the developing world. J Am Coll Radiol (2011) 1.07
Attrition from HIV testing to antiretroviral therapy initiation among patients newly diagnosed with HIV in Haiti. J Acquir Immune Defic Syndr (2013) 1.01
Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother (2013) 1.00
Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar). Vaccine (2006) 0.99
Improved prevention counseling by HIV care providers in a multisite, clinic-based intervention: Positive STEPs. AIDS Educ Prev (2009) 0.95
Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother (2009) 0.94
Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos (2007) 0.93
CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. AIDS (2016) 0.93
Medicaid home and community-based services: how consumer access is restricted by state policies. J Aging Soc Policy (2015) 0.93
Clinical trial experience with prophylactic human papillomavirus 6/11/16/18 vaccine in young black women. J Adolesc Health (2012) 0.91
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J (2015) 0.91
Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy Asthma Proc (2016) 0.90
White Paper Report of the RAD-AID Conference on International Radiology for Developing Countries: identifying challenges, opportunities, and strategies for imaging services in the developing world. J Am Coll Radiol (2010) 0.88
Endogenous opioids and chronic pain intensity: interactions with level of disability. Clin J Pain (2004) 0.86
Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect (2005) 0.86
Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing. AIDS Res Hum Retroviruses (2010) 0.86
Cerebrospinal fluid sodium rhythms. Cerebrospinal Fluid Res (2010) 0.86
Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females. Vaccine (2012) 0.85
Placental malaria and mother-to-child transmission of human immunodeficiency virus-1 in rural Rwanda. Am J Trop Med Hyg (2011) 0.84
Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clin Pharmacol Ther (2003) 0.83
Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. J Acquir Immune Defic Syndr (2002) 0.83
Near-infrared fluorescent ribonuclease-A-encapsulated gold nanoclusters: preparation, characterization, cancer targeting and imaging. Nanoscale (2012) 0.81
Which patients taking SSRIs are at greatest risk of bleeding? J Fam Pract (2006) 0.81
Effect of body mass index and ertapenem versus cefotetan prophylaxis on surgical site infection in elective colorectal surgery. Surg Infect (Larchmt) (2008) 0.81
Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr (2005) 0.80
Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy. J Acquir Immune Defic Syndr (2003) 0.79
Ventilator caregiver education through the use of high-fidelity pediatric simulators: a pilot study. Clin Pediatr (Phila) (2013) 0.79
Polymer injection therapy to reverse remodel the papillary muscles: efficacy in reducing mitral regurgitation in a chronic ischemic model. Circ Cardiovasc Interv (2010) 0.79
Microprocess examination of therapeutic immediacy during a dynamic research interview. Psychotherapy (Chic) (2011) 0.79
Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy Asthma Proc (2017) 0.79
Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist. AAPS J (2010) 0.78
Mental health self-care in medical students: a comprehensive look at help-seeking. Acad Psychiatry (2014) 0.77
Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos (2007) 0.77
Development of ethical rules for boundaries of touch in complementary medicine--outcomes of a Delphi process. Complement Ther Clin Pract (2010) 0.76
Risk, regulation and the growing marginalisation of CAM. Complement Ther Clin Pract (2009) 0.76
Reflections on the initial multinational response to the earthquake in Haiti. Popul Health Manag (2010) 0.76
Tests of the DRYAD theory of the age-related deficit in memory for context: not about context, and not about aging. Psychol Aging (2011) 0.76
Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites. AAPS J (2013) 0.75
Risk Prediction Tool for Medical Appointment Attendance Among HIV-Infected Persons with Unsuppressed Viremia. AIDS Patient Care STDS (2015) 0.75
Beyond compliance HIPAA after Anthem. Health Manag Technol (2015) 0.75
Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings. Int Arch Allergy Immunol (2017) 0.75
Sharing a vision. Building an alliance. Orthop Nurs (2004) 0.75
Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency. Am J Ther (2009) 0.75
Weight Gain in Persons with HIV Switched from Efavirenz-based to Integrase Strand Transfer Inhibitor-based Regimens. J Acquir Immune Defic Syndr (2017) 0.75
Touching ethics: assessing the applicability of ethical rules for safe touch in CAM--outcomes of a CAM (complementary and alternative medicine) practitioner survey in Israel. Complement Ther Med (2010) 0.75
An 8-week externship program designed for recruitment and retention. J Nurses Prof Dev (2014) 0.75
Integrating complementary and alternative medicine: fresh challenges for RECs. Bull Med Ethics (2002) 0.75
Withholding life-sustaining treatment: the ultimate decision. New Law J (1994) 0.75
AAPL Practice Guideline for the Forensic Assessment. J Am Acad Psychiatry Law (2015) 0.75
The association between insurance type and cost-related delay in care: a survey. Am J Manag Care (2017) 0.75
Identifying ethicolegal and professional principles in reflexology. Complement Ther Nurs Midwifery (2002) 0.75
Total dislocation of the talus: a case report. Foot Ankle Spec (2013) 0.75
When things go wrong ... what should be said? Bull Med Ethics (1998) 0.75
Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen. J Acquir Immune Defic Syndr (2002) 0.75
The role of comprehensive eye exams in the early detection of diabetes and other chronic diseases in an employed population. Popul Health Manag (2010) 0.75
Supportive psychotherapy: a crash course for medical students. Acad Psychiatry (2010) 0.75
Results of galantamine treatment in acute traumatic brain injury. Psychosomatics (2007) 0.75
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease. J Med Chem (2016) 0.75